Health care stocks were flat to slightly lower premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was down 0.01% and the iShares Biotechnology ETF (IBB) was flat recently.
Prime Medicine (PRME) shares rose nearly 19% after the company announced a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY) to develop reagents for the next generation of ex vivo T-cell therapies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。